Abstract B113: Phase I and pharmacokinetic study of ixabepilone and temsirolimus in adult patients with advanced solid tumors

Conclusions: The reasons for the unpredictable, severe toxicity of the IXB/TEM combination are unclear. The MTD could not be determined, and enrollment was discontinued. This trial exemplifies challenges associated with development of drug combinations with mTOR inhibitors.Supported in part by UM1 CA186686 and P30 CA15083. Clinical trial information: NCT01375829Citation Format: Joel M. Reid, Michael E. Menefee, Felix Boakye-Agyeman, Chad A. Walden, Charles Erlichman, Keith C. Bible. Phase I and pharmacokinetic study of ixabepilone and temsirolimus in adult patients with advanced solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B113.

Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Reid, J. M., Menefee, M. E., Boakye-Agyeman, F., Walden, C. A., Erlichman, C., Bible, K. C. Tags: mTOR / PI3-Kinase: Poster Presentations - Proffered Abstracts Source Type: research